Back to Newsroom
Back to Newsroom

Avivagen Announces Feature Article on OXC-Beta Swine Results in Ontario Hog Farmer's Magazine

Thursday, 02 October 2014 08:03 AM

Avivagen Inc.

Topic:

Ottawa, ON / ACCESSWIRE / October 2, 2014 / Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces the publication of a trade magazine article about the use of OxC-beta in Canadian swine.

The article is entitled "An alternative to antibiotics?" and appears in the current edition of Ontario Hog Farmer magazine, written by its reporter, Ms. Courtney Denard. The article cites a pilot study in 96 weaned piglets fed different levels of OxC-beta for 28 days, conducted by Dr. Dan Hurnik - Interim Dean of the Atlantic Veterinary College of the University of Prince Edward Island and Professor of Swine Health Management. Within the article, there is a discussion with Dr. Hurnik about the study results - including an 8.5% improvement in the Feed Conversion Ratio (FCR) in piglets provided 10 parts-per-million of OxC-beta in their feed. The study was funded by a contribution agreement with the Industrial Research Assistance Program of the National Research Council and has been summarized in the American Association of Swine Veterinarians Conference Proceedings.

Dr. Hurnik provided his views to Ontario Hog Farmer: "Farmers are constantly looking for products that reduce their cost of production and in our pilot study, the (fully-oxidized) beta-carotene was able to not only improve the growth rate of the pigs, but also reduce their feed needs. If we can replicate those advantages out on farms, producers would find an economical advantage to using the product."

The article proceeds to discuss Avivagen's current focus on commercializing OxC-beta in Asia, due in large part to the much greater size of Asian livestock feed markets. Further information about the article is available on Avivagen's website at www.avivagen.com.

Cameron Groome, CEO and President of Avivagen made the following comments about the Ontario Hog Farmer article and OxC-beta for swine: "We are very pleased at this interest in OxC-beta from the Ontario swine industry. In a few months, Dr. Hurnik's piglet work should be supplemented by the results of our ongoing full grow-out swine trial in Vietnam. We believe the preliminary results of the Vietnam swine study are promising - using levels of OxC-beta as low as two parts-per-million in feed. We also hope to conduct further trials of OxC-beta in Canada and ultimately register and sell our products here."

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV" and OTC Pink under the ticker symbol "CHEXF." The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and production animals by employing natural mechanisms for maintaining good health. Targeted markets include Livestock Productivity and Pet Wellness.

Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.

About OxC-beta

Avivagen's proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body's own systems to maintain and enhance health, particularly by supporting immune function. Avivagen's commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.

Research results indicate OxC-beta supports innate immune function, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, skin, coat and gut. Results observed in food animals have included healthier growth, better utilization of feed and decreased morbidity. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.

Avivagen's commercial products are OxC-beta for livestock, Vivamune(TM) Health Chews and Oximunol(TM) Chewables.

About OxC-beta for Livestock

OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to animal feeds, in accordance with Avivagen or producer-developed protocols. In past studies, OxC-beta has been shown to support health or growth in species such as fish, chicken, pigs and cattle. OxC-beta for livestock is currently available for commercial sale in the Kingdom of Thailand.

About Vivamune(TM) Health Chews - For dogs and cats

Vivamune(TM) Health Chews, containing Avivagen's proprietary active ingredients, are scientifically-formulated chews for dogs and cats. Vivamune(TM) Health Chews work with a pet's own immune system to maintain overall health and well-being. They are sold in re-sealable packages of 30 chews and are currently available in the United States by ordering on-line at www.vivamunehealth.com.

About Oximunol(TM) Chewables - For dogs

Oximunol(TM) Chewables are scientifically-formulated chewable tablets that contain Avivagen's proprietary, patented active ingredient OxC-beta. OxC-beta has been shown to stimulate innate cellular immunity and may thereby help to maintain overall health and well-being. Oximunol(TM) Chewables are distributed by Bayer Healthcare LLC and are available through veterinarians for dogs of all ages in the United States.

Permanent Non-Surgical Sterilization of Female Mammals

Avivagen has optioned worldwide exclusive rights to a technology for the permanent and non-surgical sterilization of female mammals. A proof-of-concept trial in an indicative species has been started in order to demonstrate whether the technology appears to be safe and effective. It is expected that a patent application covering World Trade Organization countries will be pursued and that technological details will be made available when that patent application is published. Further information will be disclosed as deemed prudent or as required.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "aim", "anticipated", "appear", "believe", "could", "estimated", "expected", "if", "intended", "goal", "hope", "likely", "may", "plan", "possibly", "potentially", "seem", "should", "whether", "will", "would" and similar expressions. Statements about the viability and potential future applications of the technologies described in this news release, including the nature of preliminary study results, anticipated economic benefits of such technologies, expectations for Avivagen's livestock trial study results, whether future trials will be conducted in Canada and whether products will ultimately be registered or sold in Canada or in Asia are all forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such risks and uncertainties include, but are not limited to, the following: the ability of Avivagen to continue as a going concern; the results of Avivagen's livestock trials may not be positive or as positive as the preliminary results described herein; the economic implications of study results may not be realized as suggested; even if the results of Avivagen's livestock trials are positive, there is no guarantee that Avivagen's products will be commercially viable and successful or that requisite regulatory approvals will be obtained; the timing and results of livestock trials may be delayed or may not be completed at all; and Avivagen's intellectual property rights may prove inadequate to protect its inventions. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc. - Cameron Groome, CEO & President
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Copyright (C) 2014 Avivagen

SOURCE: Avivagen Inc.

Topic:
Back to newsroom
Back to Newsroom
Share by: